Journey Colab Raises $12 Million Investment Funding To Develop Psychedelics-Based Addiction Treatment

Journey Colab raised investments valued at $12 million to support a clinical trial of a psychedelic combined with psychosocial therapy and community support for addiction treatment. The company seeks to gain approval for the treatment model from the U.S. Food and Drug Administration (FDA). The company’s lead compound is synthetic mescaline HCl. It has potential as a treatment to reach durable remission for alcohol use disorder.

Journey Colab was founded in 2020. On July 19, 2022, the company announced the appointment of Joel A. Posener, M.D. as chief medical officer. In his previous role at Neumora, he . . .